Healthcare Nov 19, 2021 02:32 PM (GMT+8) · EqualOcean
Yiouda health on November 19, today, Guangzhou mingmed Biotechnology Co., Ltd. announced that its first in class tumor immune target HPK1 small molecule inhibitor prj1-3024 has passed the ind procedure of FDA and is officially carrying out phase I clinical trial in the United States. At the same time, Yinming biological announced that its first in class ophthalmic new drug qa102 for dry age-related macular degeneration (dry AMD) in the United States has successfully completed the administration of all subjects in the phase I clinical trial. It is reported that qa102 is aimed at dry age-related macular degeneration, a blinding eye disease that has no cure worldwide.